(PharmaNewsWire.Com, October 12, 2021 ) According to research report "Thrombectomy Market by Type (Hydrodynamic, Ultrasound, Aspiration, Mechanical Thrombectomy), Application (Cardiovascular, Peripheral, Neurovascular), End User (Hospitals, Surgical Centers, Ambulatory, Academia, CROs) - Global Forecasts to 2022", This report studies the thrombectomy devices market over the forecast period of 2017 to 2022. The market is expected to reach USD 1.45 Billion by 2022 growing at a CAGR of 6.7%.
Browse 67 market data tables and 75 figures spread through 174 pages and in-depth TOC on "Thrombectomy Market by Type (Hydrodynamic, Ultrasound, Aspiration, Mechanical Thrombectomy), Application (Cardiovascular, Peripheral, Neurovascular), End User (Hospitals, Surgical Centers, Ambulatory, Academia, CROs) - Global Forecasts to 2022"
On the basis of type, the global thrombectomy devices market is segmented into aspiration, mechanical/fragmentation, rheolytic/hydrodynamic, and ultrasonic thrombectomy devices. The mechanical/fragmentation thrombectomy devices segment accounted for the largest share of the market in 2016. This large share is attributed to the ongoing commercialization of mechanical thrombectomy products, favorable reimbursement scenario, established therapeutic efficacy, growing market demand for stent retrievers among medical professionals, and rising end-user preference for minimally invasive thrombectomy procedures.
On the basis of application, the global Thrombectomy Market is segmented into neurovascular, cardiovascular, and peripheral vascular applications. The cardiovascular applications segment accounted for the largest share of the market in 2016. The large share of this segment is attributed to the increasing prevalence of cardiovascular diseases, procedural benefits offered by mechanical thrombectomy in cardiac surgeries, higher prevalence of thrombotic diseases among geriatric individuals, and growing preference of surgeons for image-guided and minimally invasive cardiac surgeries.
On the basis of end users, the global thrombectomy devices market is segmented into hospitals & surgical centers, ambulatory surgical centers, research laboratories & academic institutes, and other end users. The highest CAGR of the ambulatory surgical centers segment is mainly attributed to increasing availability of reimbursement for thrombectomy procedures in outpatient settings, ongoing advancements in minimally invasive surgical techniques, increasing number of image-guided surgeries performed at ASCs, and rising market demand for miniaturized therapeutic devices.
On the basis of geography, this market is classified into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, the global Thrombectomy Market was dominated by North America; mainly due to significant adoption of technologically advanced thrombectomy products, growing number of clinical trials, and significant medical reimbursement available in the U.S. for thrombectomy procedures.
However, Asia-Pacific market is expected to grow at the highest CAGR during 2017-2022. This is primarily due to the presence of large target patient population, increasing healthcare expenditure, increase in localized manufacturing & strengthening of distribution networks, and rising awareness among surgeons related to the benefits offered by thrombectomy devices.
In 2016, Stryker Corporation (U.S.), Medtronic Plc (U.S.), Boston Scientific Corporation (U.S.), Penumbra, Inc. (U.S.) Johnson & Johnson (U.S.), Terumo Corporation (Japan), Spectranetics Corporation (U.S.), Edwards Lifesciences Corporation (U.S.), Argon Medical Devices, Inc. (U.S.), and Teleflex Incorporated (U.S.) are some of the key players in Thrombectomy Market.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
